Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced today that after
review of the Company’s white paper on development of AEOL-10150 as a
countermeasure for the lung effects of acute radiation syndrome, the
Biomedical Advanced Research and Development Authority (BARDA) Division
of Chemical, Radiological and Nuclear (CBRN) Countermeasures has
informed the Company that, after careful analysis and consideration, it
has invited Aeolus to submit a full proposal for a contract to develop
AEOL 10150 from its current level of technical readiness to FDA
approval. The invitation to submit a proposal by BARDA and Aeolus’
proposal are non-binding, and the selection of the Company’s white paper
for submission of a full proposal is not a guarantee of a contract,
which will be subject to a favorable technical and scientific review and
negotiation of fair and reasonable contract terms.
“To this end we have conducted studies of AEOL 10150 in collaboration
with Duke University, the University of Maryland and a NIAID-sponsored
Research Consortium focused on major organ-specific sub-syndromes of ARS
and delayed effects of acute radiation exposure establishing proof of
principle”
Aeolus submitted its white paper, “Advanced Development of AEOL 10150 as
a Medical Countermeasure for Pulmonary Injury Associated with ARS and
DEARE,” to BARDA on August 31, 2009 consistent with the Special
Instructions Amendment 4 to a Broad Agency Announcement
(BAA-BARDA-09-34) for advanced research and development of medical
countermeasures for chemical, biological, radiological and nuclear
threats. The purpose of the special instructions amendment is to
specifically solicit solutions for treating cutaneous and/or pulmonary
(life-threatening pneumonitis and fibrosis) injuries resulting from
exposure to ionizing radiation. BARDA is interested in advanced
development and eventual licensure/approval of medical countermeasures
for cutaneous and/or pulmonary injuries resulting from an acute exposure
to radiation from a radiological/nuclear accident or attack,
particularly injuries associated with Acute Radiation Syndrome (ARS) or
Delayed Effects of Acute Radiation Exposure (DEARE).